APPLICATION

Human Sure-RACE cDNA 5 End Discovery Panels

Human Sure-RACE Discovery Panels are assembled from 24 major tissues. RACE-ready cDNAs are provided in two concentrations (5x and 1x) to accommodate the analysis of both rare and abundant transcripts. They are arrayed in a 48-well (6 x 8 wells) PCR plate in the order indicated (Fig. 2).

Fig 2

This panel was used to analyze the 5' end sequences of transcripts from the highly expressed transferrin receptor gene (Fig. 3). The results show a single major component of the appropriate size in virtually every tissue, as well as minor components of heterogeneous sizes that were derived from cDNAs with truncated 5' ends. When the template concentration was reduced to one-fifth, the latter components became less detectable.

Fig 3

The Sure-RACE Human Discovery Panel can be used to complete the 5'-end sequences of long and rare transcripts with extensive secondary structure (Fig. 4). The ataxia telangiectasia (ATM) gene encodes an ubiquitous 12-kb transcript with extensive conformations and somewhat heterogeneous 5' ends.

Fig 4

Mouse Sure-RACE cDNA 5 End Discovery Panels

Mouse Sure-RACE Discovery Panels are assembled from 24 major tissues and varied developmental stages. Adult tissues are prepared from outbred Swiss Webster mice and breast tissues from outbred CD1 mice. The RACE-ready cDNAs are provided in two concentrations (5x and 1x) to accommodate the analysis of both rare and abundant transcripts and arrayed in a 48-well (6 x 8 wells) PCR plate in the order indicated (Fig. 5).

Fig 5

This product can be used to discover alternate RNA startsites derived from different tissue-specific transcriptional promotors (Fig. 6). The intercellular adhesion molecule-1 (ICAM-1) gene uses different promoters to initiate transcription.

Fig 6

This product can also be used to identify differentially spliced transcripts that contain alternate 5' exons that are utilized in different tissues (Fig. 7). The fibroblast growth factor 1 (FGF-1) gene makes use of different 5' exons to regulate its expression.

Fig 7